Information  X 
Enter a valid email address

JPMorgan Japanese IT (JFJ)

  Print      Mail a friend       Annual reports

Friday 17 January, 2020

JPMorgan Japanese IT

Result of AGM

RNS Number : 2191A
JPMorgan Japanese Inv. Trust PLC
17 January 2020
 

LONDON STOCK EXCHANGE ANNOUNCEMENT

 

JPMORGAN JAPANESE INVESTMENT TRUST PLC

 

RESULTS OF POLL AT ANNUAL GENERAL MEETING

 

17th JANUARY 2020

 

 

Legal Entity Identifier: 549300JZW3TSSO464R15

Information disclosed in accordance with LR 9.6.18

 

 

Results of Resolutions

 

Following the Annual General Meeting of the Company, which was held today, the Board is pleased to announce that all of the Ordinary Resolutions put to shareholders were voted on by Poll and passed.  In addition, the following items of Special Business was also voted on by Poll and passed which:

 

i)          allow the Company to allot new Ordinary shares up to an aggregate nominal amount of £4,031,200 representing approximately 10% of the Company's issued Ordinary share capital;

ii)         allow the Company to dis-apply pre-emption rights on allotment of relevant securities; and

iii)        allow the Company to make market purchases of up to 24,171,085 Ordinary shares, representing 14.99% of the Company's issued share capital.

The full text of all the resolutions can be found in the Notice of Annual General Meeting contained in the Annual Report & Financial Statements which is available for viewing at the National Storage Mechanism which can be located at www.morningstar.co.uk/uk/NSM and from the Company's website, www.jpmjapanese.co.uk. 

A Summary of proxy votes received will shortly be available on the Company's website, www.jpmjapanese.co.uk. 

 

17th January 2020.

 

For further information, please contact:

 

Faith Pengelly

For and on behalf of

JPMorgan Funds Limited

Company Secretary

020 7742 4000 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
RAGSFDFIWESSEEF

a d v e r t i s e m e n t